| Profile: |
AstraZeneca (NYSE:AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site. In total, AstraZeneca's R&D organization is comprised of more 11,500 people located in seven countries including Canada, France, India, Japan, Sweden, United Kingdom and the United States.
With marketing activities all over the world, AstraZeneca Pharmaceuticals LP is headquartered in Wilmington, Delaware (USA). AstraZeneca has manufacturing activities in more than 20 countries. The company has approximately 60,000 employees worldwide, 20,000 of whom are involved in marketing and selling products to health care professionals.
AstraZeneca - Leading with Research
With more than 100 years of combined experience, scientists at AstraZeneca have discovered and developed many of today's leading prescription medicines-pharmaceuticals which contribute to a higher quality of life for millions of patients and to a better health economy worldwide.
AstraZeneca's R&D organization is international in scope and comprised of approximately 11,500 researchers and support staff. Through its own resources and through collaboration with scores of universities and strategic alliances with numerous research and biotechnology companies, AstraZeneca has broad access to advanced technologies in biomedical research, including genomics, bioinformatics, chemical libraries, high throughput screening and product delivery systems. The Global Discovery Alliance group, through a network of Discovery Licensing Directors, work in a cooperative effort to provide optimal access to external science and technologies in support of AstraZeneca's overall research strategy.
AstraZeneca - Leading with Products
AstraZeneca's success ratio of bringing new products to market is among the best in the pharmaceutical industry. The company produces a wide range of products that make significant contributions to treatment options and patient care. AstraZeneca has one of the world's leading portfolios to treat cancer and gastrointestinal disorders, in addition to the areas of cardiovascular, infection, neuroscience, and respiratory and inflammation.
With numerous projects in the R&D pipeline, and many more to follow, the company is well equipped to maintain a flow of high quality medicines over the coming years. These medicines will offer improved health and quality of life for patients, better health economics for society and attractive growth for AstraZeneca.
In addition to the development of new products, we continue to explore all the ways our existing product range can be used or improved. Through this active lifecycle management of our product range, we can realize the full potential of all our medicines.
For a complete list of career opportunities please visit: CLICK HERE
|
